ARTICLE | Clinical News

Custirsen sodium: Completed Phase III enrollment

September 22, 2014 7:00 AM UTC

OncoGenex completed enrollment in the open-label, international Phase III AFFINITY trial comparing IV custirsen plus Jevtana cabazitaxel and prednisone vs. Jevtana plus prednisone in about 630 CRPC patients who progressed after first-line treatment with docetaxel. Patients will receive 3 loading doses of 640 mg custirsen, followed by 640 mg custirsen given weekly in 3-week cycles. Custirsen has Fast Track designation in the U.S. in combination with Jevtana and prednisone to treat CRPC following treatment with a docetaxel-containing regimen. ...